Daniel Talley is a staff scientist/medicinal chemist in the Early Translation Branch within NCATS’ Division of Preclinical Innovation, where his research focuses on identifying flawed biological pathways common to multiple diseases/disorders and on developing small-molecule modulators to restore cellular homeostasis and function. This often involves medicinal chemistry optimization of hit compounds, usually identified via quantitative high-throughput screening and/or machine learning and employing pharmacophore-based screening and quantitative structure-activity relationship studies. He also has significant experience in developing and synthesizing small-molecule probes for target deconvolution and mechanism of action studies.
In addition, Talley works to site-specifically and stoichiometrically modify human Immunoglobulin Gs for subsequent versatile conjugation to payloads, including small-molecule probes or drugs, fluorescent and near-infrared dyes, peptides and other antibodies.
Talley earned his Bachelor’s degree in biochemistry from Salisbury University and his doctorate in organic chemistry from the University of Maryland, Baltimore County.
- Rabies virus
- Modulators of endoplasmic reticulum dislocation
- Hepatitis C virus
- Niemann-Pick disease type C
- Platforms for drug delivery and localization
- Antibody conjugation